^
Association details:
| Biomarker: | ASXL1 deletion |
|---|---|
| Cancer: | Myelodysplastic Syndrome |
| Drug: | azacitidine (DNA methylation inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations
Published date:
07/22/2021
Excerpt:
ASXL1DEL /ASXL1MUT patients were correlated by univariable analysis with a worse response to AZA.
DOI:
10.1111/bjh.17675
